Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
Molecular Analysis for Therapy Choice (MATCH)
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for whom no standard treatment exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.
First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
Feasibility Trial of Preoperative 5 Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma
To determine the feasibility of preoperative 5-day HFRT for extremity STS within the HCC patient population
To evaluate the rates of favorable pathologic response, major woundcomplications, local control, acute toxicity, and 1-year late toxicity
associated with preoperative 5-day HFRT
To compare the socio-demographic profile of trial participants with those
of extremity STS patients who would have meet trial criteria and were
offered preoperative CFRT in the 3 years prior to the study opening at HCC
To compare the retention rate for radiotherapy at HCC in patients meeting
trial criteria during the prior 3 years with the retention rate for
radiotherapy during the study period
To compare serum levels of SFRP2 before and after preoperative 5-day
To evaluate changes in serum SFRP2 levels before and after preoperative
5-day HFRT for an association with favorable pathologic response
To evaluate patient satisfaction with the decision to participate in a trial of
preoperative 5-day HFRT
To assess the importance of the shorter duration of radiotherapy in an
individual patient?s decision to participate in the study